Public Perceptions Related to Healthcare Preparedness to Anti-Amyloid Therapies for Alzheimer’s Disease in Japan

Author:

Sato Kenichiro1,Niimi Yoshiki2,Ihara Ryoko3,Iwata Atsushi3,Suzuki Kazushi4,Nemoto Kiyotaka5,Arai Tetsuaki5,Higashi Shinji6,Igarashi Ataru7,Kasuga Kensaku8,Awata Shuichi9,Iwatsubo Takeshi1

Affiliation:

1. The University of Tokyo

2. The University of Tokyo Hospital

3. Tokyo Metropolitan Institute for Geriatrics and Gerontology

4. National Defense Medical College

5. University of Tsukuba

6. Tokyo Medical University

7. Yokohama City University School of Medicine

8. Niigata University

9. Integrated Research Initiative for Living Well with Dementia

Abstract

Abstract

Background The approval of lecanemab, an anti-amyloid therapy for Alzheimer’s disease (AD), necessitates addressing healthcare preparedness for disease-modifying treatment (DMT) to ensure appropriate, safe, and sustainable drug administration. Understanding public perceptions on this matter is crucial. We aimed to assess discrepancies and similarities in the perceptions of Japanese trial-ready cohort study (‘J-TRC webstudy’) participants and clinical specialists in the fields of dementia treatment and radiology, concerning affairs related to challenges in DMT preparedness. Methods This was a cross-sectional prospective observational study conducted in November-December 2023. The J-TRC webstudy participants were invited to participate in an online survey using Google Forms, and clinical specialists were invited to complete a mail-based survey. Main questionnaire items had been designed to be common in both surveys, and their responses were analyzed for participant attributes, interests, attitudes, expectations, and concerns about DMTs without specifying lecanemab. Results Responses were obtained from n = 2,050 J-TRC webstudy participants and n = 1,518 clinical specialists. Compared to specialists, more J-TRC respondents perceived the eligible proportion for DMT as smaller (59.1% versus 30.7%), perceived the eligible severity for DMT as more limited (58.0% versus 24.5%), and perceived the efficacy of DMT as slightly more encouraging (29.3% versus 34.8%). In terms of treatment prioritization, both J-TRC respondents and specialist respondents exhibited similar levels of acceptance for prioritizing patients to treat: e.g., approximately two-thirds endorsed patient prioritization under hypothetical resource constraints or other reasons. A medical rationale emerged as the most compelling reason for acceptance of patient prioritization across the surveys. In contrast, the need to address vulnerable populations was the reason that led to the least acceptance of prioritization, followed by socioeconomic considerations. Conclusions Our findings offer valuable insights into the discrepancies in knowledge and perception between patients and healthcare providers. This could enhance the delivery of patient information in clinical settings and inform the discussion surrounding patient prioritization strategies.

Publisher

Springer Science and Business Media LLC

Reference27 articles.

1. Advances in Alzheimer's disease research over the past two decades;Jack CR;Lancet Neurol,2022

2. Lecanemab: Appropriate Use Recommendations;Cummings J;J Prev Alzheimers Dis,2023

3. Eisai. LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan. (https://www.eisai.com/news/2023/news202359.html): Accessed on September 25, 2023.

4. Biogen. LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China. (https://investors.biogen.com/news-releases/news-release-details/leqembir-lecanemab-approved-treatment-alzheimers-disease-china) : Accessed on January 9, 2024.

5. LEQEMBI® Intravenous Infusion (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20;Eisai

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3